Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series

Le X 1 , Eisert A 2 , Hsia TC 3 , Raut NV 4 , Ahmad A 5 , Chan OSH 6 Show all authors , De Bondt C 7 , Farrugia D 8 , Froesch P 9 , González-Cao M 10 , Hendriks L 11 , Hochmair MJ 12 , Mazieres J 13 , O'Sullivan H 14 , Popat S 15 , Samol J 16 , van der Wekken AJ 17 , Yang TY 18 , Tho LM 19 , Himpe U 20 , Lam WS 21 , Lee KWC 22 , Petrini I 23 , Berghoff K 24 , Karachaliou N 25 , Joshi K 26 , Vlassak S 27 , Chang GC 28

Affiliations 

  • 1 Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: XLe1@mdanderson.org
  • 2 Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, Cologne, Germany
  • 3 Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
  • 4 Bhaktivedanta Hospital and Research Centre, Mumbai, India
  • 5 Beacon Hospital, Selangor, Malaysia
  • 6 Department of Clinical Oncology, Hong Kong Integrated Oncology Centre, Hong Kong
  • 7 Department of Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium
  • 8 Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, United Kingdom
  • 9 Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland
  • 10 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain
  • 11 Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Reproduction, Maastricht, Netherlands
  • 12 Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria
  • 13 Toulouse University Hospital, Pneumology Department, Université Paul Sabatier, Toulouse, France
  • 14 Department of Medical Oncology, Cork University Hospital, Cork, Ireland
  • 15 Lung Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom
  • 16 Department of Medical Oncology, Tan Tock Seng Hospital, Singapore; Lee Kong Chian School of Medicine, Singapore; School of Medicine, Johns Hopkins University, Baltimore, MD, USA
  • 17 Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
  • 18 Division of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
  • 19 Department of Oncology, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 20 Department of Pulmonary Diseases, AZ Delta, Roeselare, Belgium
  • 21 Western Haematology and Oncology Clinics, West Perth, Australia
  • 22 Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong
  • 23 Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy
  • 24 Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany
  • 25 Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany
  • 26 Global Development Operations, the healthcare business of Merck KGaA, Darmstadt, Germany; ICON plc, Dublin, Ireland
  • 27 Global Medical Affairs, Merck N.V.-S.A., Overijse, Belgium, an affiliate of Merck KGaA, Darmstadt, Germany
  • 28 School of Medicine and Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan
Clin Lung Cancer, 2025 Feb 21.
PMID: 40140342 DOI: 10.1016/j.cllc.2025.02.013

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications